StockDrifts LogoStockDrifts

D&D Pharmatech 347850

Company
디앤디파마텍D&D Pharmatech
Insiders
2
Buys
61
Total Value
₩2.8B ($1.9M)
Avg Return
-46.72%
Last Filing
2026-10-23

D&D Pharmatech (347850) has 61 disclosed insider purchases and 10 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩2.8B ($1.9M) in reported transaction value. The earliest filing StockDrifts holds for D&D Pharmatech is dated 2024-05-02; the most recent is 2026-10-23. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -46.72%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-10-23BUYMarket Buy
한설희
Seolhee Han
Outside Director5---
2026-06-04BUY주식매수청구권 행사
박평아
Park Pyeong-ah
Managing Director2.4K₩94,000-12.2%₩226M ($157K)
2026-06-04BUY주식매수청구권 행사
신재희
Jaehee Shin
moving56.0K₩94,000-12.2%₩5.3B ($3.7M)
2026-06-04BUY주식매수청구권 행사
임성묵
Seongmuk Lim
Managing Director38.0K₩94,000-12.2%₩3.6B ($2.5M)
2026-05-13BUYMarket Buy
한설희
Seolhee Han
Outside Director300₩68,200-1.3%₩20M ($14K)
2026-05-11BUYMarket Buy
한설희
Seolhee Han
Outside Director40₩70,700-4.8%₩3M ($2K)
2026-05-08BUYMarket Buy
한설희
Seolhee Han
Outside Director60₩70,800-4.9%₩4M ($3K)
2026-05-04BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩74,900-10.2%₩7M ($5K)
2026-04-30BUYMarket Buy
한설희
Seolhee Han
Outside Director500₩74,200-9.3%₩37M ($26K)
2026-04-28SELLMarket Sell
한설희
Seolhee Han
Outside Director-125₩78,700+14.5%₩10M ($7K)
2026-04-27BUYMarket Buy
한설희
Seolhee Han
Outside Director15₩81,800-17.7%₩1M ($852)
2026-04-24BUYMarket Buy
한설희
Seolhee Han
Outside Director10₩81,800-17.7%₩818K ($568)
2026-04-23BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩79,700-15.6%₩8M ($6K)
2026-04-20SELLMarket Sell
한설희
Seolhee Han
Outside Director-228₩82,000+17.9%₩19M ($13K)
2026-04-17BUYMarket Buy
한설희
Seolhee Han
Outside Director12₩78,900-14.7%₩947K ($658)
2026-04-16BUYMarket Buy
한설희
Seolhee Han
Outside Director486₩81,600-17.5%₩40M ($28K)
2026-04-15BUYMarket Buy
한설희
Seolhee Han
Outside Director30₩79,800-15.7%₩2M ($2K)
2026-04-13BUYMarket Buy
한설희
Seolhee Han
Outside Director50₩76,400-11.9%₩4M ($3K)
2026-04-10BUYMarket Buy
한설희
Seolhee Han
Outside Director46₩74,000-9.1%₩3M ($2K)
2026-04-09BUYMarket Buy
한설희
Seolhee Han
Outside Director44₩68,700-2.0%₩3M ($2K)
2026-04-08BUYMarket Buy
한설희
Seolhee Han
Outside Director54₩69,800-3.6%₩4M ($3K)
2026-04-07BUYMarket Buy
한설희
Seolhee Han
Outside Director6₩67,600-0.4%₩406K ($282)
2026-04-06BUYMarket Buy
한설희
Seolhee Han
Outside Director200₩66,300+1.5%₩13M ($9K)
2026-04-03BUYMarket Buy
한설희
Seolhee Han
Outside Director8₩68,600-1.9%₩549K ($381)
2026-04-02BUYMarket Buy
한설희
Seolhee Han
Outside Director12₩69,400-3.0%₩833K ($578)
2026-04-01BUYMarket Buy
한설희
Seolhee Han
Outside Director70₩74,900-10.2%₩5M ($4K)
2026-03-26BUYMarket Buy
한설희
Seolhee Han
Outside Director10₩78,500-14.3%₩785K ($545)
2026-03-25BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩79,100-14.9%₩8M ($5K)
2026-03-23BUYMarket Buy
한설희
Seolhee Han
Outside Director47₩70,300-4.3%₩3M ($2K)
2026-03-20BUYMarket Buy
한설희
Seolhee Han
Outside Director138₩78,100-13.8%₩11M ($7K)
2026-03-19BUYMarket Buy
한설희
Seolhee Han
Outside Director65₩78,900-14.7%₩5M ($4K)
2026-03-17BUYMarket Buy
한설희
Seolhee Han
Outside Director50₩83,500-19.4%₩4M ($3K)
2026-03-13BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩92,300-27.1%₩9M ($6K)
2026-03-11BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩80,200-16.1%₩8M ($6K)
2026-03-06BUYMarket Buy
한설희
Seolhee Han
Outside Director90₩83,900-19.8%₩8M ($5K)
2026-03-05BUYMarket Buy
한설희
Seolhee Han
Outside Director360₩82,200-18.1%₩30M ($21K)
2026-02-26BUYMarket Buy
한설희
Seolhee Han
Outside Director20₩88,800-24.2%₩2M ($1K)
2026-02-25BUYMarket Buy
한설희
Seolhee Han
Outside Director30₩88,700-24.1%₩3M ($2K)
2026-02-24BUYMarket Buy
한설희
Seolhee Han
Outside Director98₩88,600-24.0%₩9M ($6K)
2026-02-23BUYMarket Buy
한설희
Seolhee Han
Outside Director202₩86,500-22.2%₩17M ($12K)
2026-02-20BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩84,900-20.7%₩8M ($6K)
2026-02-10BUYMarket Buy
한설희
Seolhee Han
Outside Director200₩79,200-15.0%₩16M ($11K)
2026-02-06BUYMarket Buy
한설희
Seolhee Han
Outside Director200₩77,500-13.2%₩16M ($11K)
2026-02-03BUYMarket Buy
한설희
Seolhee Han
Outside Director299₩90,300-25.5%₩27M ($19K)
2026-01-28SELLMarket Sell
한설희
Seolhee Han
Outside Director-2.0K₩99,300+32.2%₩199M ($138K)
2026-01-26BUYMarket Buy
한설희
Seolhee Han
Outside Director500₩96,700-30.4%₩48M ($34K)
2026-01-23BUYMarket Buy
한설희
Seolhee Han
Outside Director300₩85,800-21.6%₩26M ($18K)
2026-01-22BUYMarket Buy
한설희
Seolhee Han
Outside Director300₩79,300-15.1%₩24M ($17K)
2026-01-21BUYMarket Buy
한설희
Seolhee Han
Outside Director200₩80,100-16.0%₩16M ($11K)
2026-01-20BUYMarket Buy
한설희
Seolhee Han
Outside Director100₩89,700-25.0%₩9M ($6K)

Showing the 50 most recent of 97 filings.

Frequently asked questions

Who has been buying D&D Pharmatech stock?
2 distinct insiders have filed 61 disclosed insider purchases in D&D Pharmatech (347850), most recently on 2026-10-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does D&D Pharmatech have?
D&D Pharmatech has 61 buy-side and 10 sell-side disclosures on record, covering ₩2.8B ($1.9M) in total reported value, spanning 2024-05-02 to 2026-10-23.
Where does StockDrifts get D&D Pharmatech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for D&D Pharmatech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.